Explore a little further

FDA

Stories and perspectives from Daytrade News.

From Daytrade News

6 stories shown · Newest added
Daytrade News

CRISPR Therapeutics Faces Stock Challenges Despite Analyst Optimism

CRISPR Therapeutics has seen its stock price decline over the past year, trading significantly below Wall Street's price targets. Analysts predict potential gains, with one projecting an 86% upside based on the company's gene therapy product, CASGEVY, which has shown strong reve…

More perspectives

Across our publications

A selection of related stories